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Recently, pharmacokinetic investigation has played an increasingly important role in drug discovery. In particular, it is very important to predict human hepatic metabolic clearance because most drugs are eliminated from the body predominantly by hepatic metabolism. For predicting hepatic clearance, theoretical aspects of in vitro/in vivo scaling based on a physiological model and clearance concepts have been developed (Roberts and Rowland, 1986) . Application of this method has been successful in predicting in vivo hepatic clearance in rats for many drugs metabolized by P450 1 from in vitro metabolism data using rat liver microsomes and isolated hepatocytes (Sugiyama et al., 1988; Houston and Carlile, 1997) . Because human liver samples have become more readily available, it would also be very useful to predict in vivo outcomes from in vitro data in humans. However, there has been relatively limited application of this approach (Hoener, 1994) , and there have been some failed attempts at the prediction of human hepatic clearance. For example, Iwatsubo et al. (1997) and Houston and Carlile (1997) reported that CL int,in vitro generally exhibited a positive correlation with CL int,in vivo , but in some cases animal or human clearance values were not well predicted from in vitro studies. To improve the predictions of human hepatic clearance, a few investigators have described new methods and approaches. For example, Lave et al. (1997) have proposed allometric scaling techniques combined with in vitro data. Obach (1999) has reported that inclusion of microsome binding values in the prediction of clearance from in vitro data seems to be a more broadly applicable approach. Recently, we also investigated the quantitative prediction of human hepatic metabolic clearance from in vitro experiments using liver microsomes focusing on P450 metabolism with eight model compounds (Naritomi et al., 2001) . The values of CL int,in vitro and CL int,in vivo for each model compound were compared in rats and/or dogs, and humans. As a result, 1) scaling factor values, which are the ratios of CL int,in vivo to CL int,in vitro , were similar in the different animal species; 2) scaling factor values were different for each compound; 3) successful predictions of human CL int,in vivo were obtained by considering animal scaling factor; and 4) use of human CL int,in vitro corrected with animal scaling factor produced good predictions of CL oral and E H in humans. Namely, the empirical prediction method is a simple one of incorporating additional information (which is compound-specific) from animal studies and is based on the assumption that any in vitro-in vivo difference seen in humans is also apparent in animals to approximately the same degree.
It is helpful to use hepatic microsomes for evaluating compounds metabolized by P450. In contrast to microsomes, intact hepatocytes contain phase I (P450), phase II (conjugative) enzymes, and their cofactors. In addition, it seems that the use of hepatocytes can eval-uate the involvement of active transporters. Accordingly, isolated hepatocytes provide an in vitro system for studying the integrated metabolism and distribution of compounds. Some studies have reported the prediction of hepatic clearance from in vitro experiments using freshly isolated hepatocytes, especially in rats (Ashforth et al., 1995; Carlile et al., 1998) . However, there has been limited application of the prediction using human freshly isolated hepatocytes (Bayliss et al., 1999) . In general, there is limited availability of fresh human livers for research. Cryopreservation would greatly enhance the utility of human hepatocytes because cryopreserved hepatocytes could be used at any time for experiments. Successful cryopreservation of human hepatocytes has been reported by several researchers (Chesne et al., 1993; Coundouris et al., 1993) . However, there have been few reports on the prediction of hepatic clearance using human cryopreserved hepatocytes.
In the present study, we examined CL int,in vitro obtained from in vitro experiments using hepatocytes and CL int,in vivo calculated from in vivo pharmacokinetic data with nine model compounds (FK1052, FK480, diazepam, diltiazem, troglitazone, quinotolast, FK079, zidovudine, and acetaminophen) in rats and humans. In particular, we evaluated CL int,in vitro using cryopreserved hepatocytes in humans. At the same time, the measurement method of CL int,in vitro , which is determined from substrate disappearance rate at 1 M in hepatocytes, was used because it is a simple and useful method.
Materials and Methods
Chemicals. FK1052, FK480, troglitazone, quinotolast, and FK079 were synthesized by Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). Diltiazem hydrochloride, zidovudine, and acetaminophen were purchased from SigmaAldrich (St. Louis, MO). Diazepam was purchased from Wako Pure Chemicals (Osaka, Japan). The other regents and solvents used were of analytical and HPLC grade.
Selection of Model Compounds. FK1052, FK480, diazepam, diltiazem, troglitazone, quinotolast, FK079, zidovudine, and acetaminophen ( Fig. 1) were selected as the model compounds based on the following criteria: clearance of model compounds is determined by hepatic P450, UDP-glucuronosyltransferase, sulfotransferase, and/or esterase metabolism; extrahepatic clearances are assumed to be negligible; in vivo pharmacokinetic parameters in rats and humans are reported; and extent of absorption is good with no species difference.
Preparation of Freshly Isolated Rat Hepatocytes. Adult male SpragueDawley rats and Wistar-Imamichi rats (200 -250 g; n ϭ 3) were obtained from Charles River Japan Inc. (Yokohama, Japan) and Imamichi Institute for Animal Reproduction (Ibaraki, Japan), respectively. Rat hepatocytes were freshly prepared by the in situ collagenase perfusion method as described previously (Tanaka et al., 1978) . The cells were suspended in Williams' medium E (WME) containing L-glutamine (2 mM) purged with 95% O 2 , 5% CO 2 . Cell viability was assessed by the trypan blue exclusion test and preparations that were more than 80% viable were used. The viability of freshly isolated rat hepatocytes used was 84.7 Ϯ 2.7%.
Cryopreserved Rat and Human Hepatocytes. Cryopreserved rat and human hepatocytes were obtained from In Vitro Technologies Inc. (Baltimore, MD). Rat hepatocytes that were the pooled preparations of 24 adult male Sprague-Dawley rat livers were used. Eleven cryopreserved human hepatocytes (race, Caucasian; age, 33-69 years; male, six donors and female, five donors) were used for the evaluation. Of the human hepatocytes, human hepatocytes from five to seven individual donors were used for each model compound. These hepatocytes were stored in liquid N 2 until use. Thawing was achieved by gently shaking the vials of cryopreserved hepatocytes in a 37°C water bath. As soon as all contents had been thawed, the vials were placed immediately on ice and diluted with WME at 4°C. After dilution, the hepatocyte suspension was washed by centrifugation at 50g for 5 min and resuspended in WME (Ruegg et al., 1997) . The viability of cryopreserved rat and human hepatocytes used was 51.3 Ϯ 1.7 and 73.9 Ϯ 7.5%, respectively.
In All assay methods were in the concentration range of 0.1 to 2 M. Reproducibility was evaluated by performing five replicate analyses of hepatocyte samples containing 0.1, 0.5, and 1 M compound, respectively. The coefficient of variation was less than 10%, and the actual concentration of the compounds ranged from 97.5 to 106%. All assay methods thus provide good accuracy and precision.
Calculation of CL int,in vitro . CL int,in vitro values were calculated from substrate disappearance rate in hepatocytes as follows. If substrate disappearance can be assumed to follow first-order reaction, the unchanged drug profile as a function of time [C(t)] is described as follows.
where C 0 is initial concentration of the compound, k e is the disappearance rate constant of unchanged drug (min Ϫ1 ). Furthermore, initial metabolic rate (V 0 ) (micromoles per minute per cell) is described by eq. 2:
where D cell is the cell density (cells per milliliter).
On the other hand, from the Michaelis-Menten equation, V 0 is described by the eq. 3:
If the substrate concentration used in the experiments (1 M) is below the K m for the drug-metabolizing enzyme reactions, the drug concentration may be assumed to be much smaller than K m (K m Ͼ Ͼ C 0 ). Thus, V 0 can be expressed by eq. 4:
Consequently, Table 1 into consideration. In Vivo Data. Sources of pharmacokinetic data. In vivo clearance under linear conditions, f u and R B data, were obtained from in-house and published literature. The in vivo pharmacokinetic data were considered to be trustworthy because the in vivo pharmacokinetic experiments were performed based on good accuracy methods and the appropriate protocols. In vivo clearance value was calculated by dividing the dose by area under the curve. In the case of high-clearance compounds, CL oral was used, because CL int,in vivo calculated from CL tot is affected by changes of Q H (Iwatsubo et al., 1997) . For FK480 and diazepam, which are intermediate-clearance drugs in rats, CL oral was also used in the same way as the in vitro-in vivo scaling using hepatic microsomes (Naritomi et al., 2001) . When the in vivo clearance value was not expressed per kilogram of body weight, this value was converted so that it was expressed per kilogram of body weight by taking the mean value of body weight in published literature or body weight of 250 g, 10 kg, and 70 kg for rats, dogs, and humans, respectively. F a of FK1052, FK480, quinotolast, and FK079 were estimated by summing the recoveries of radioactivity in bile and urine after oral administration of 14 C model compounds to rats from our own data. F a for diazepam, diltiazem, troglitazone, zidovudine, and acetaminophen were estimated from published data. FK1052, FK480, diazepam, and diltiazem were evaluated as the compounds metabolized mainly by P450. Troglitazone, quinotolast, FK079, zidovudine, and acetaminophen were evaluated as the compounds metabolized by different drug-metabolizing enzymes ( Table 2) .
Calculation of CL int,in vivo . CL H values were determined from eqs. 6 and 7 by use of the CL tot and CL oral values, respectively. For quinotolast, CL H in rats were calculated from pharmacokinetic parameters after administration into femoral vein and hepatic portal vein (Katashima et al., 1993a) . CL R was considered to be negligible for FK1052, FK480, diazepam, diltiazem, quinotolast, troglitazone, and FK079. 
CL int,in vivo was calculated from the following equations using the well stirred (Pang and Rowland, 1977) and dispersion models (Roberts and Rowland, 1986) :
Well-stirred model:
Disperison model:
E H was calculated from eq. 14:
Estimation of Scaling Factor and Prediction of Human CL int,in vivo . Scaling factor was estimated from the following equation:
Scaling factor ϭ CL int,in vivo /CL int,in vitro (15)
Human CL int,in vivo were predicted based on human CL int,in vitro using the following two methods: 1) disregarding rat scaling factor, Predicted human CL int,in vivo ϭ human CL int,in vitro (16) and 2) including rat scaling factor, Predicted human CL int,in vivo ϭ human CL int,in vitro ⅐ rat scaling factor (17)
Binding of Model Compounds to Isolated Rat Hepatocytes. Determination of f u,hepatocytes . Binding to isolated rat hepatocytes was determined using the hepatocyte reaction mixture described above. After adding each model compound (final concentration, 1 M) to the hepatocyte suspension, the mixture was placed into a centrifuge tube containing a mixture of silicone and mineral oil (density, 1.017) and centrifuged (10,000g for 10 s) at room temperature. The cells were separated through the oil layer, and the supernatant fraction was removed with a pipette (Yamazaki et al., 1993) . All procedures were completed within 1 min, so that metabolism of the model compound in the hepatocytes could be neglected, and the concentration of the model compound in the supernatant fraction could be determined (Lin et al., 1980) .
Calculation of CL uint,in vitro and the scaling factor. By incorporating the correction with the unbound fraction in the hepatocyte incubation mixture, CL uint,in vitro is defined as (Obach, 1999) :
The value of scaling factor, which is the ratio of CL int,in vivo to CL uint,in vitro , was calculated from eq. 15.
Results
In Vivo Pharmacokinetic Data for Model Compounds. In vivo pharmacokinetic data for the model compounds are summarized in Table 2 . The fractions absorbed from the intestinal tract (F a ) were high, in the range of 0.7 to 1.0. The values of unbound fraction in plasma (or serum) (f p ) ranged widely from the highest values for zidovudine (f p : rat, 0.786; human, 0.8) and acetaminophen (f p : rat, 0.82; human, 0.79) to the lowest value for troglitazone (f p : rat, 0.000921; human, 0.000941). In vivo clearance, CL int,in vivo and E H values differed markedly between rats and humans for each compound. For example, FK480 and diazepam are characterized by intermediate to high E H (0.62 and 0.64) in rats. On the contrary, low E H values (0.12 and 0.03) were observed in humans. In vivo rat and human E H ranged widely among the model compounds (rat: 0.05 for FK079 and ϳ0.93 for FK1052; human: 0.03 for diazepam and ϳ0.76 for diltiazem). The model compounds represented a variety of metabolic pathways. FK1052, FK480, diazepam, and diltiazem are metabolized mainly by P450. In contrast, quinotolast, FK079, and zidovudine were metabolized by UDP-glucuronosyltransferase or esterase besides P450. Troglitazone and acetaminophen were metabolized mainly by UDP-glucuronosyltransferase and sulfotransferase. Of the compounds metabolized by different drug-metabolizing enzymes, some compounds showed species differences in the elimination routes and metabolite profiles. For example, FK079 is metabolized mainly by P450 in rats and by esterase in humans, respectively (Tokuda et al., 1997) . For zidovudine, approximately 75 and 10% of the dose were excreted as its unchanged and glucuronide in rats, respectively (Mays et al., 1991) . On the other hand, approximately 14 and 75% of the dose were excreted as its unchanged and glucuronide in humans, respectively (Blum et al., 1996) . For acetaminophen, the primary route of metabolism is glucuronidation in rats and sulfation in humans, respectively (Hjelle and Klaassen, 1984; Sonne et al., 1988) .
In Vitro Metabolism in Rat Hepatocytes and Estimation of Scaling Factor. Fig. 2 illustrates the time courses of the unchanged model compounds in freshly isolated rat hepatocytes. The time courses were estimated by use of Sprague-Dawley rat hepatocytes, except for troglitazone. For troglitazone, the time course was estimated by use of Wistar-Imamichi rat hepatocytes, because the in vivo pharmacokinetic data in Wistar-Imamichi rats were used for evaluation. The unchanged drug profiles at 1 M showed linear log concentration declines so that the metabolism follows a first-order reaction under these conditions. Table 3 shows the CL int,in vitro calculated from the time courses of the model compounds in freshly isolated rat hepatocytes and the values for rat scaling factor (the ratios of CL int,in vivo obtained from in vivo pharmacokinetic data to CL int,in vitro ). The rat scaling factor values calculated using the well stirred model were about 73.1-fold for troglitazone, 43.6-fold for FK1052, 25.1-fold for FK480, 10.5-fold for quinotolast, 6.1-fold for FK079, and 0.5-to 2.2-fold for diazepam, diltiazem, zidovudine, and acetaminophen, showing a marked difference among the model compounds. In the same way, the rat scaling factor values calculated using the dispersion models were 0.2-to 47.1-fold, showing marked differences among the model compounds. Table 4 shows the unbound fraction in freshly isolated rat hepatocytes, rat CL uint,in vitro corrected with f u,hepatocytes and the scaling factor values. Rat f u,hepatocytes values were determined by use of Sprague-Dawley rat hepatocytes, except for the f u,hepatocytes value for troglitazone, which was determined by use of Wistar-Imamichi rat hepatocytes. Rat f u,hepatocytes values were dependent on the model compounds. For example, although FK1052, FK480, and troglitazone were highly bound to hepatocytes with free-fraction values ranging Figure 3 shows the correlation between CL int,in vitro for the model compounds in freshly isolated and cryopreserved rat hepatocytes. CL int,in vitro values in freshly isolated hepatocytes were determined using Sprague-Dawley rat hepatocytes. For most of the model compounds, the CL int,in vitro in freshly isolated hepatocytes were in good agreement with those in cryopreserved hepatocytes.
In Vitro Metabolism in Cryopreserved Human Hepatocytes and Prediction of Human CL int,in vivo . Fig. 4 illustrates the values of CL int,in vitro in cryopreserved human hepatocytes for the model compounds. The CL int,in vitro values were expressed per kilogram of body weight by taking physiological parameters in Table 1 into consideration. There were significant interindividual differences in CL int,in vitro estimated in cryopreserved human hepatocytes from five to seven donors for each compound. The mean values of CL int,in vitro among the model compounds also ranged widely from undetectable for quinotolast to 72.4 ml/min/kg for diltiazem. For quinotolast, the CL int,in vitro values could not be detected because evident concentration declines of the unchanged compound were not observed. For this reason, prediction of human CL int,in vivo mentioned below was evaluated except for quinotolast. Table 5 shows predicted CL int,in vivo and the differences between observed and predicted CL int,in vivo in humans. The predicted CL int,in vivo values were estimated from the human CL int,in vitro corrected value with or without rat scaling factor. Without consideration of rat scaling factor, the differences showed various values (2.2-199.0-fold) among the model compounds. For FK1052, FK480, troglitazone, and FK079, the differences were especially large (FK1052, 135.6 -199.0-fold; FK480, 32.2-33.7-fold; troglitazone, 117.4 -148.4-fold; and FK079, 12.4 -15.8-fold) , resulting in discrepancies between CL int,in vitro and CL int,in vivo . In contrast, with rat scaling factor (Table 3) , most of the values corrected were within 5-fold, except for FK1052 [10.9-fold (dispersion model)] and diltiazem [8.1-fold (well stirred model) and 11.0-fold (dispersion model)], significantly improving the predictability of human CL int,in vivo .
Discussion
In the present study, we investigated CL int,in vitro obtained from in vitro experiments using hepatocytes and CL int,in vivo calculated from in vivo pharmacokinetic data with nine model compounds (FK1052, FK480, diazepam, diltiazem, troglitazone, quinotolast, FK079, zidovudine, and acetaminophen) in rats and humans. As a result, 1) rat scaling factor values (CL int,in vivo /CL int,in vitro ) were different among the compounds; 2) when human CL int,in vitro was regarded as the predicted CL int,in vivo , the observed and predicted CL int,in vivo differed markedly for some compounds; and 3) use of human CL int,in vitro corrected with rat scaling factor improved the predictability of human CL int,in vivo .
In this study, CL int,in vitro values were estimated using hepatocytes. In drug discovery, enzymes involved in the metabolism of compounds are not sufficiently characterized. Compared with subcellular fractions such as hepatic microsomes, hepatocytes seem to be suitable for measuring CL int,in vitro , because they possess a larger complement of drug-metabolizing enzymes. In addition, the hepatocyte system is a useful tool to evaluate compounds that are metabolized by multiple drug-metabolizing enzymes. Therefore, we selected model compounds metabolized by various enzymes, such as P450, esterase, UDP-glucuronosyltransferase, and sulfotransferase, to confirm the advantage of hepatocytes (Table 2 ). Of the model compounds, trogli-
FIG. 3. Correlation of CL int,in vitro between freshly isolated and cryopreserved rat hepatocytes.
The dotted lines represent the lines of unity. Each compound (at a concentration 1 M) was incubated for various time periods at 37°C in freshly isolated rat hepatocytes. The values for cell density in the reaction mixtures were 0.5 ϫ 10 6 cells/ml (FK1052, FK480, diazepam, diltiazem, quinotolast, and troglitazone), 1 ϫ 10 6 cells/ml (acetaminophen), 2 ϫ 10 6 cells/ml (zidovudine), and 4 ϫ 10 When rat CL int,in vitro were evaluated using freshly isolated rat hepatocytes, rat scaling factor values for a few drugs (diazepam, diltiazem, zidovudine, and acetaminophen) were close to unity (Table 3) . However, the values for some drugs (FK1052, FK480, quinotolast, troglitazone, and FK079) were from 6.0 to 73.1, resulting in CL int,in vivo values larger than the CL int,in vitro values (Table 3) . These findings suggest that CL int,in vivo values are not always in agreement with the CL int,in vitro values. In the same way, when using cryopreserved human hepatocytes, the differences between observed and predicted human CL int,in vivo for FK1052, FK480, troglitazone, and FK079 were especially large (12.4 -199.0-fold) (Table 5) , resulting in discrepancies between CL int,in vitro and CL int,in vivo .
Several studies have reported the use of freshly isolated rat hepatocytes to predict quantitative hepatic clearance (Ashforth et al., 1995; Carlile et al., 1998) . However, there have been few studies of prediction using freshly isolated human hepatocytes (Bayliss et al., 1999) . CL int,in vitro values were estimated in cryopreserved human hepatocytes using five to seven donors for each compound and expressed per kilograms of body weight by taking physiological parameters in Table 1 into One reason is that there is a limited availability of fresh human livers for research. Thus, human hepatocytes are not yet widely used as an experimental system. In this respect, cryopreservation is especially important for hepatocytes from species such as humans, where tissue supply is limited. There are several reports of the cryopreservation of human hepatocytes (Chesne et al., 1993; Coundouris et al., 1993) . Furthermore, a few groups have reported the evaluation of metabolic pathways, enzyme induction, and inhibition using cryopreserved human hepatocytes applied to drug metabolism research (Ruegg et al., 1997; Li et al., 1999; Hewitt et al., 2001 ). For predicting hepatic metabolic clearance using cryopreserved hepatocytes, there is a requirement that CL int,in vitro (or drug-metabolizing enzyme activity) in cryopreserved hepatocytes is in agreement with that in the freshly isolated hepatocytes. In this study, we compared CL int,in vitro in freshly isolated and cryopreserved rat hepatocytes for the model compounds. As a result, for most of the compounds, the CL int,in vitro in the freshly isolated hepatocytes were in good agreement with those in the cryopreserved hepatocytes (Fig. 3) . In addition, Li et al. (1999) have reported that cryopreserved human hepatocytes had equivalent enzyme activities for P450 (CYP1A2, 2A6, 2C9, 2C19, 2D6, and 3A4), UDP-glucuronosyltransferase, and sulfotransferase to their corresponding freshly isolated human hepatocytes. Judging from these results, it is reasonable to use cryopreserved hepatocytes for predicting hepatic metabolic clearance.
CL int,in vitro was determined from substrate disappearance rate at a single drug concentration (1 M) in hepatocytes. The measurement method can be thought of as a simple and useful method with advantages of the method as follows: 1) simple to conduct, 2) can be done for many compounds, 3) metabolites do not need to be known, 4) can be easily done without radiolabeling, and 5) can yield enzyme kinetic data based on the disappearance of parent compounds. On the other hand, disadvantages of the method are as follows: 1) it is difficult to measure very low CL int,in vitro values; 2) do not get individual metabolite information; and 3) do not obtain K m and V max parameters (Naritomi et al., 2001 ). We could not detect CL int,in vitro for quinotolast in human hepatocytes because the CL int,in vitro values were very low (Fig. 4) . In this case, it is difficult to predict CL int,in vivo quantitatively. However, it seems reasonable to assume that the predicted CL int,in vivo in humans was very low in comparison with that in rats, from a qualitative level.
Previously, we reported the quantitative prediction of human hepatic clearance using hepatic microsomes for compounds metabolized by P450 (Naritomi et al., 2001) . As a result, we found that use of human CL int,in vitro corrected with rat and/or dog scaling factors yielded better predictions of human CL int,in vivo . In this study, we have examined the effect of rat scaling factor in the case of using hepatocytes. Without consideration of rat scaling factor, some compounds showed marked differences between observed and predicted human CL int,in vivo , as mentioned above. In contrast, with rat scaling factor, most of the differences were within 5-fold (Table 5 ). These results indicate that it is likely that the prediction method using human hepatic materials, which includes animal scaling factors, improves predictability. However, the differences were more than 2-fold except for FK480 (1.3-1.9-fold) ( Table 5 ). Increasing the accuracy of the predictability requires the improvement of the prediction method. In addition, the results were obtained by use of the limited compounds. In the future, we would improve the prediction method for many more compounds and confirm its validity.
When using hepatic microsomes, inclusion of dog scaling factor also improved the predictability of human CL int,in vivo (Naritomi et al., 2001) . In the present study, we evaluated the prediction by use of hepatocytes, focusing on the application of rat scaling factor. To give a better human prediction, future studies should also examine the prediction applying dog scaling factor. A major problem facing researchers using hepatocytes from the livers of larger species such as dogs and humans is the scarcity of tissue available. Recently, cryopreservation of dog hepatocytes has been reported (Swales and Utesch, 1998) . Use of cryopreserved dog hepatocytes would be useful in prediction studies.
At the present time, it is not clear why each compound has an intrinsic scaling factor. However, there are a few possible reasons. To begin with, f u,hepatocytes in the reaction mixture may have an influence on the CL int,in vitro values. For in vitro-in vivo scaling, correction with f u in the reaction mixture has been reported to be important (Lin et al., 1980; Obach, 1999) . Therefore, we have evaluated f u,hepatocytes of the model compounds in rats and the changes in scaling factor values when correcting with f u,hepatocytes . However, CL int,in vitro corrected with f u,hepatocytes were not in agreement with the CL int,in vivo for some compounds. Namely, the scaling factor values for FK1052, FK480, troglitazone, quinotolast, and FK079 still showed high values, 3.1-to 15.8-fold (Table 4 ). This suggests that a scaling factor different from unity might not be due only to the drug binding to hepatocytes. The following assumptions in the mathematical models may relate to the result: 1) a rapid equilibrium between blood and hepatocytes, 2) availability of only unbound drug for elimination and transport across membranes, and 3) homogeneous distribution of metabolic enzymes and transport carriers along the blood flow pathways in the liver (Iwatsubo et al., 1996) . If any of these assumptions are incorrect, discrepancies between CL int,in vivo and CL int,in vitro will be observed.
In conclusion, we investigated CL int,in vitro obtained from in vitro experiments using freshly isolated or cryopreserved hepatocytes and compared with CL int,in vivo calculated from in vivo pharmacokinetic data with nine model compounds in rats and humans. When using freshly isolated rat hepatocytes, rat scaling factor values (CL int,in vivo /CL int,in vitro ) showed marked difference among the model compounds. Human CL int,in vitro were determined by use of cryopreserved hepatocytes. When human CL int,in vitro was regarded as the predicted CL int,in vivo , the observed and predicted CL int,in vivo for some drugs differed markedly. In contrast, use of human CL int,in vitro corrected with rat scaling factors improved the predictability of human CL int,in vivo . These results make the evaluation using hepatocytes more useful and provide a basis for predicting hepatic clearance using hepatocytes.
